Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,897 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06006013RecruitingPhase 2
Cabozantinib and pembrolizumab for adrenal cancer
This trial tests a combination of two drugs (cabozantinib and pembrolizumab) for adrenal cancer that has spread or cannot be removed by surgery. It may be an option if you have not had treatment before or have already tried other therapies.
Atlanta, GeorgiaAges 18 years+ - NCT06004245RecruitingPhase 1
Study of new drug for advanced solid tumors with certain genetic markers
This trial is testing a new oral medication, VVD-133214, for people with advanced solid tumors that have a specific genetic feature called MSI-high or dMMR. The study will see if the drug is safe and effective when given alone or with other drugs like bevacizumab or pembrolizumab.
Tucson, ArizonaAges 18 years+ - NCT06028074RecruitingPhase 1/Phase 2
Study of GIM-122 for advanced solid tumors
This trial tests a new drug, GIM-122, in people with advanced solid tumors that have stopped responding to or cannot tolerate standard PD-1/PD-L1 inhibitors. The goal is to see if GIM-122 is safe and tolerable.
Los Angeles, CaliforniaAges 18 years+ - NCT05981703RecruitingPhase 1
Study of BGB-26808 alone or with tislelizumab for advanced solid tumors
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT05984147RecruitingPhase 1
Study of oral drug AUR108 for advanced lymphoma
This trial tests an experimental oral drug called AUR108 for people with advanced lymphoma that has come back after at least two prior treatments. The goal is to see if the drug is safe and if it can help shrink or control the lymphoma.
Visakhapatnam, Andhra PradeshAges 18–99 - NCT06001749RecruitingPhase 2
Psilocybin for cancer pain study
This trial tests whether psilocybin (a psychedelic drug) can help with severe cancer pain. You may qualify if your pain is high despite strong medications and you are willing to be monitored closely.
Boston, MassachusettsAges 18 years+ - NCT05998330Recruiting
Palliative care support for advanced liver disease patients
This study tests whether adding palliative care (extra support for symptoms and planning) during a hospital stay helps people with advanced liver disease and their caregivers feel better and plan ahead.
Boston, MassachusettsAges 18 years+ - NCT05957536RecruitingPhase 1
Testing a new drug for HER2-positive advanced solid cancers
This Phase 1 trial tests D3L-001 alone in people with HER2-positive advanced solid tumors. It’s mainly looking to see how the drug works and how safe it is in this group.
Stanford, CaliforniaAges 18 years+ - NCT05967689RecruitingPhase 2
Zipalertinib for lung cancer with EGFR exon 20 mutations
This Phase 2 trial tests zipalertinib (a targeted pill) in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations, especially “exon 20 insertions.” It may help shrink tumors or slow cancer growth, including in some people with brain metastases.
Birmingham, AlabamaAges 18 years+ - NCT05954312RecruitingPhase 1
Study of an experimental drug for advanced solid tumors
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Jacksonville, FloridaAges 18 years+ - NCT05944224RecruitingPhase 1/Phase 2
SPH4336 for advanced solid tumors with or without immunotherapy
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
Fuzhou, FujianAges 18–75 - NCT05939934Recruiting
Test a mouth device for sleep apnea after stopping CPAP
This study looks at whether a mandibular advancement device (a fitted mouthpiece) can control sleep apnea when you temporarily stop CPAP. It’s mainly for people who have been using CPAP for over a year but are now willing to try the mouth device.
AngersAges 18–75 - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT05914545RecruitingPhase 1
Early study drug for advanced solid tumors in adults
This Phase 1 trial tests a new experimental medicine (FZ-AD004) in adults with advanced solid tumors. It aims to see how the drug behaves in the body and whether it’s safe enough to continue in patients with measurable cancer.
HangzhouAges 18–75 - NCT05897125Enrolling by invitation
Telehealth education to help people with COPD after a hospital stay
This study tests whether a telehealth (video/phone) education program can help people with COPD better manage their health after a hospital flare-up. It may reduce the chance of needing to return to the hospital soon after discharge.
Chicago, IllinoisAges 18 years+ - NCT05888532RecruitingPhase 1/Phase 2
Testing a copper-based scan and treatment in advanced cancers
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
San Francisco, CaliforniaAges 18 years+ - NCT05886920RecruitingPhase 1/Phase 2
Study drug for advanced cancers with specific MAPK changes
This Phase 1/2 study tests a new drug (D3S-002) to see if it can shrink or control advanced cancers that have certain MAPK pathway gene changes. It may help people whose cancer has progressed despite standard treatments, especially in a specific lung cancer group.
Detroit, MichiganAges 18 years+ - NCT05903833RecruitingPhase 2
Study pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
AugsburgAges 18 years+ - NCT05884255RecruitingPhase 3
Lutetium brain-sparing therapy for advanced gut and pancreas tumors
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05547321RecruitingPhase 1
New cancer drug plus immunotherapy for advanced solid tumors
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Boston, MassachusettsAges 18 years+ - NCT05875168RecruitingPhase 1/Phase 2
Study of DS-3939a for Advanced Solid Tumors
This trial is testing a new drug called DS-3939a for people with advanced solid tumors that have not responded to other treatments. The study has two parts to find the right dose and see how well it works.
Sarasota, FloridaAges 18 years+ - NCT05860465RecruitingPhase 2/Phase 3
Tested blood cancer medicine with hormone therapy for breast cancer
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
Guangzhou, GuangdongAges 18–75 - NCT05867420RecruitingPhase 1/Phase 2
ASKG915 for advanced solid tumors that stopped responding
This early-stage study tests ASKG915, a new treatment, for people with advanced solid cancers that are no longer responding to standard care (or don’t have standard options). If you may qualify, you’d be screened with recent health tests to check safety and eligibility, and then receive the study drug.
New York, New YorkAges 18 years+ - NCT05856981RecruitingPhase 1
Testing ADU-1805 for advanced solid tumors safety
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Detroit, MichiganAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,897 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.